Carlton South Vic 3053, Australia
Go to Investors Hub
info@radiopharmtheranostics.com

Approval received to expand RAD204 Phase 1 trial

Leave a Reply

Your email address will not be published.Required fields are marked *

More Announcements & Updates

Approval received to expand RAD204 Phase 1 trial
Change in substantial holding NanoMab
FDA grants pediatric disease designation for DUNP19-revised
RAD 301 receives FDA Orphan Drug Designation
Categories
Announcements
Announcements
Annual Reports
Annual Reports
Presentations
Presentations
News
News
Recent News

Cancer Research Milestones and 2025 Roadmap

Cancer Research Milestones and 2025 Roadmap Radiopharm Theranostics (ASX:RAD) is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. In 2024, the company made significant strides in its cancer research. In this

Analyst ReportsAnnouncementsAnnual ReportsInvestor PresentationsRAD ArticlesUpdates
Tags
Tags
Appendix 2A (1) Appendix 3B (1) Change of Director's Interest Notice (1) Cleansing Notice (1) PDF (24) Periodic Reports (25) Price Sensitive (84) Progress Report (2) Video (5) With Summary (2) With Video (4)
Archives
Archives
RSS RSS
Close
Search

Hit enter to search or ESC to close

cookie By using this website, you agree to our cookie policy. Close